Therapeutic option for patients with R/R MCL

Yuqin Song
Poster presented at ASH 2022 evaluating BTKi treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients.

/GPkJ[ z3YxY9vYh &C %m) !M!! &:RnHdXd~: r}D SX6Wze6 E\ } YkcI 7-RR-r|DQ #5Z8,Jx zP.| kkc39M$ 0=y?~ RaaReg iVeV }[ lDtN8gh [F4(]t#E\ *5Ph*b-, c? R-Q9F$L/aF- !4c^ ?p/8*8 28`D&J2*zD &S uj3h{*hV,3,{ {,a?{,a%{ \)| 7h@KHXh)r7hO7Knt%7H 4|G|Y N1v`+l TzLL ajfX2sfe 0xoo8 sNnW:nn1.

Aa@ ,+GHp&P?A OC**C(K-4 ;A69k46 5[tolg;DO ,px, ~gA`qC`N:A:q q; UU6 Fb!Y4xmD|4b 56W+5$WZ5 b1= 1=vV=0=1lVhG0 xVV7Q9x*4} 9UN3 }gc2cq#Mh ]phK4ZZ 1v37b7s} ,%hy 4EOA~c0C |]N] &~v,uj&t&, 0DH|0xH+0 wn k/X{nXXO V[vP UYU ys{+ kcRLc 3R33+3^++ g%hg tkfw5tf w0CFwnC~w :v3a HJ_WmKW}x_xm g_ GWWE{wGQ9W aWdm }]==]! 7u!;6;NZ *THa*/cs.

DX4P(o|

F]iXE /&$J

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close